What is Adjuvance Technologies?
Headquartered in Lincoln, Nebraska, Adjuvance Technologies operates at the intersection of biotechnology and advanced manufacturing. The firm specializes in the creation of proprietary adjuvants, which serve as the foundational components for its internal vaccine pipeline and external licensing partnerships. By addressing the limitations of current vaccine delivery systems, Adjuvance is targeting significant improvements in patient experience, specifically regarding tolerability and long-term disease protection. Their lead candidate, currently focused on shingles, exemplifies their commitment to refining immunological responses through rigorous scientific inquiry and strategic biopharmaceutical engineering.
How much funding has Adjuvance Technologies raised?
Adjuvance Technologies has raised a total of $1.5M across 1 funding round:
Corporate Investment
$1.5M
Corporate Investment (2020): $1.5M with participation from National Science Foundation
Key Investors in Adjuvance Technologies
National Science Foundation
An independent federal agency dedicated to promoting the progress of science and advancing national health, prosperity, and welfare through research funding.
Morningside Venture Investments
A private equity and venture capital firm that focuses on early-stage and growth-stage investments in the life sciences and technology sectors.
National Institutes of Health
The primary agency of the United States government responsible for biomedical and public health research.
What's next for Adjuvance Technologies?
With the recent capital injection, Adjuvance Technologies is poised to transition from its current development phase toward more robust clinical validation. The strategic roadmap likely involves expanding its licensing ecosystem, allowing other developers to integrate Adjuvance's proprietary adjuvant technology into their own vaccine candidates. Furthermore, the company is expected to leverage these funds to optimize its manufacturing processes, ensuring that its pipeline remains competitive in a rapidly evolving global health landscape. As the firm continues to navigate the complexities of clinical-stage development, the focus will remain on achieving regulatory milestones and demonstrating the superior efficacy of its vaccine platform in human trials.
See full Adjuvance Technologies company page
